



Charlotte A.E. Hauser is a Professor of Bioscience and the Chair of the Bioengineering Program at King Abdullah University of Science and Technology (KAUST), Thuwal, Saudi Arabia. Before joining KAUST, she was a Principal Investigator at the Institute of Bioengineering and Nanotechnology, A*Star, Singapore, and Adjunct Professor at Nanyang Technological University, Singapore. Trained as a chemist, she did her Ph.D. in Molecular Biology at the Massachusetts Institute of Technology (MIT) and the University of Cologne, Germany, then joined INSERM in Paris, and later the Max-Planck-Institute of Psychiatry in Munich, Germany. She was a Founder and Managing Director of Octagene in Munich/Martinsried, Germany. There, she developed the first fourth generation human recombinant coagulation factor VIII (hFVIII). This recombinant human clotting factor NUWIQ® is the newest hFVIII replacement and since 2014 on the market. She is a Fellow of the American Institute for Medical and Biological Engineers (AIMBE) and since 2015 a Fellow of the US National Academy of Inventors (NAI). In 2016, she started the KAUST spin-off company PepPrint. Her research includes molecular self-assembly, synthetic peptide biomaterials, novel inhibitor compounds for neurodegenerative diseases, and regenerative therapies as well as 3D bioprinting.

<https://nanomedicine.kaust.edu.sa/>